Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma

Recruiting now · Phase 1

Conditions studied: Extranodal Natural Killer/T Cell Lymphoma

In brief

This is an open-label, phase Ib study evaluating the combination treatment of sintilimab and linperlisib in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (NKTCL).

Key facts

Study ID

NCT06793956

Run by

Sun Yat-sen University

People needed

12

Starts

2025-02-21

Expected to finish

2030-01-31

Last updated by the study team

2025-03-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sun Yat-sen Universitiy Cancer Center — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.